Erik Ingelsson, MD, PhD

Chief Scientific Officer

Dr. Ingelsson joined Wave in 2024 as Chief Scientific Officer. At Wave, he is responsible for driving the company’s emerging therapeutic portfolio strategy, including growing its genetics and genomics capabilities for identifying new, high impact targets, and leveraging the company’s best-in-class multimodal discovery and development platform to advance transformative RNA medicines.

Prior to joining Wave, Dr. Ingelsson was at GSK and served as Senior Vice President (SVP), Head of Target Discovery, and prior to that, SVP of Genomic Sciences. While at GSK, he led a team focused on a large-scale, industrialized approach to target discovery and validation, bringing together functional genomics, chemical biology, structural biology, and protein and cellular sciences to drive drug discovery and development. His organization worked across all therapeutic areas at GSK.

Before joining GSK, Dr. Ingelsson was Professor of Medicine at Stanford University. His lab used human genetics and functional genomics to discover novel biology and drug targets related to insulin resistance and related conditions, such as obesity, MASH, and cardiovascular disease. His work combined large-scale human genetics studies with in-depth pre-clinical validation work and an emphasis on cardiometabolic diseases.

Dr. Ingelsson obtained his MD and PhD at Uppsala University, Sweden. After clinical internship and residency, he undertook postdoctoral research at the Framingham Heart Study before joining the faculty at Karolinska Institutet (Stockholm, Sweden), where he was appointed Professor of Cardiovascular Epidemiology. He was also Professor of Molecular Epidemiology at Uppsala University and was a visiting professor at Oxford University. He has published over 400 peer-reviewed original articles and has an h-index of 145.